Current respiratory syncytial virus prevention strategies in high-risk infants

Pediatrics International

Volumn 44, Issue 5, 2002, Pages 475-480

  Weisman, Leonard E ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Immunoprophylaxis; Newborn infant; Premature infant; Prevention; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ACTIVE IMMUNIZATION; CLINICAL TRIAL; HIGH RISK POPULATION; HUMAN; IMMUNOPROPHYLAXIS; INFECTION CONTROL; INFECTION PREVENTION; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; REVIEW; RISK FACTOR;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; INFANT, NEWBORN; INFECTION CONTROL; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RISK FACTORS; VIRAL VACCINES;

EID: 0036378285     PISSN: 13288067     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-200X.2002.01613.x     Document Type: Review

References (49)

1. Morris JA, Blount RE Jr, Savage RE. Recovery of cytopathic agent from chimpanzees with coryza. Proc. Soc. Exper. Biol. Med. 1956; 92: 544-9.
2. Channock R, Finberg L. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA): II. Epidemiologic aspects of infection in infants and young children. Am. J. Hyg. 1957; 66: 291-300.
3. Channock R, Rozman B, Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties, characterization. Am. J. Hyg. 1957; 66: 281-90.
4. Centers for Disease Control. U.S. seasonal RSV epidemics. Morbidity Mortality Weekly Rev. 1997; 46: 1163-65.
5. Meissner HC, Welliver RC, Chartrand SA, Fulton DR, Rodriguez WJ, Groothuis JR. Prevention of respiratory syncytial virus infection in high-risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin. Pediatr. Infect. Dis. J. 1996; 15: 1058-68.
6. Weisman LE, Groothius JR (eds). Introduction. In: Contemporary Diagnosis and Management of Respiratory Syncytial Virus. Handbooks in Health Care, Newton, PA, 2000.
7. Wang EE, Law BJ, Robinson JL et al. PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) study of the role of age and respiratory syncytial virus micro-neutralizing antibody on RSV illness in patients with underlying heart or lung disease. Pediatrics 1997; 99: E9.
8. Imaizumi S, Agrawal S, Pereira GR. Severity of RSV infection in hospitalized premature infants: the effect of gestational age and immune prophylaxis with palivizumab. Pediatr. Res. 2001; 49: 2311.
9. Boyce TG, Mellen BG, Mitchel EF Jr., Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J. Pediatr. 2000; 137: 865-70.
10. Law BJ, DeCarvalho V. Respiratory syncytial virus infections in hospitalized Canadian children: regional differences in patient populations and management practices. The Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr. Infect. Dis. J. 1993; 12: 659-63.
11. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am. J. Respir. Crit. Care Med. 2000; 161: 1501-7.
12. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B, Bjorksten B. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics 1995; 95: 500-5.
13. Simoes E. Treatment and prevention of respiratory syncytial virus lower respiratory tract infection. Long-term effects on respiratory outcomes. Am. J. Respir. Crit. Care Med. 2001; 163 (3 Pt 2): S14-17.
14. Kimpen JL, Simoes E. Respiratory syncytial virus and reactive airway disease. New developments prompt a new review. Am. J. Respir. Crit. Care Med. 2001; 163 (3 Pt 2): S1.
15. Piedimonte G. Neural mechanisms of respiratory syncytial virus-induced inflammation and prevention of respiratory syncytial virus sequelae. Am. J. Respir. Crit. Care Med. 2001; 163 (3 Pt 2): S18-21.
16. Welliver RC. Immune Response. In: Weisman LE, Groothius JR (eds). Contemporary Diagnosis and Management of Respiratory Syncytial Virus. Handbooks in Health Care, Newton, PA, 2000; 94-121.
17. Cunnigham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants of less than 32 weeks gestation. Pediatrics 1991; 88: 527-32.
18. Yuksel B, Greenough H. Birth weight and hospital readmission of infants born prematurely. Arch. Pediatr. Adolesc. Med. 1994; 148: 384-8.
19. Emond AM, Howat P, Evans JA, Hunt L. The effects of housing on the health of preterm infants. Paediatr. Perinat. Epidemiol. 1997; 11: 228-39.
20. PREVENT Study Group. Reduction of respiratory syncytial virus hospitalizations among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997; 99: 93-9.
21. Smith Kline Beecham (SKB). Data report, 1997.
22. IMpact RSV Study Group. Palivizumab a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-7.
23. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 1969; 89: 405-21.
24. Crowe JE Jr. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza viruse (PIV). Vaccine 1995; 13: 415-21.
25. Crowe JE Jr. Future prevention strategies. In: Weisman LE, Groothius JR (eds). Contemporary Diagnosis and Management of Respiratory Syncytial Virus. Handbooks in Health Care, Newton, PA, 2000; 176-200.
26. Glezen WP, Paredes A, Allison J, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J. Pediatr. 1981; 98: 708-15.
27. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 1986; 140: 543-6.
28. Siber GR, Leombruno D, Leszczynski J. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J. Infect. Dis. 1994; 169: 1368-73.
29. AAP. Respiratory syncytial virus immune globulin intravenous: indications for use. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn. Pediatrics 1997; 99: 645-50.
30. Johnson S, Oliver C, Prince GA et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 1997; 176: 1215-24.
31. Beeler JA, van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J. Virol. 1989; 63: 2941-50.
32. Branco L, Barren P, Gross R et al. Development of a broadly reactive humanized monoclonal antibody for the prevention of severe lower respiratory tract disease caused by respiratory virus. European Society of Pediatric Infectious Diseases. 1999, 21-23 May; Crete, Greece.
33. Subramanian KN, Weisman LE, Rhodes T et al. Safety, tolerance and pharmacokinetics of a humanized respiratory syncytial virus (RSV) monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr. Infect. Dis. J. 1998; 17: 110-15.
34. Saez-Llorens X, Castano E, Null D et al. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr. Infect. Dis. J. 1998; 17: 787-91.
35. AAP. Prevention of respiratory syncytial virus infections. Indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn. Pediatrics 1998; 102: 1211-16.
36. Meissner HC, Welliver RC, Chartrand SA et al. Immunoprophylaxis with palivizumab, humanized respiratory sycytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high-risk infants: a consensus opinion. Pediatr. Infect. Dis. J. 1999; 18: 223-31.
37. Sorrentino M, Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group. Pediatr. Infect. Dis. J. 2000; 19: 1068-71.
38. Cohen AH, Sorrentino M, Powers T. Effectiveness of palivizumab for preventing serious RSV disease. J. Resp. Dis. Pediatriancs 2000; 2(Supp 4): S30-32.
39. R Outcomes Registry. 5th World Congress of Perinatal Medicine; 2002 Sept 23-27; Barcelona, Spain, Abstract # 1714.
40. Reach Survey 1998-1999 (Data provided by MedImmune).
41. Oh PI, Lanctot KL, Yoon A et al. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr. Infect. Dis. J. 2002; 21: 512-18.
42. van Kan CI, Eenhoorn PC, Zweens MJ, Woltil HA, Baarsma R. Palivizumab surveillance: an evaluation of RSV-related hospitalization of high-risk children after palivizumab prophylaxis in the Netherlands during 1999-2000 RSV season. 5th World Congress of Perinatal Medicine; 2002 Sept 23-27; Barcelona, Spain, Abstract # 1851.
43. R) over a first and second respiratory sycytial virus season. 5th World Congress of Perinatal Medicine; 2002 Sept 23-27; Barcelona, Spain, Abstract # 880.
44. Hudak M, Chartrand S, The Synagis Outcome Registry. Perinatal Section of the American Academy of Pediatrics Annual Meeting; 2001 Oct 20; San Francisco, California, Abstract # 17369.
45. Groothuis JR, Lepez EL, Tressler R, and the Southern Hemisphere Expanded Access Group. Expanded Access Study with palivizumab in 1999 - Southern Hemisphere (data provided by Abbott Laboratories).
46. Groothuis JR, and the Northern Hemisphere Expanded Access study Group. Safety and tolerance of palivizumab administration in a large northern hemisphere trial. Pediatr. Infect. Dis. J. 2001; 20: 628-30.
47. Marchetti A, Lau H, Magar R, Wang L, Devercelli G. Impact of palivizumab on expected costs of respiratory sycytial virus infection in preterm infants: potential for savings. Clin. Ther. 1999; 21: 752-66.
48. Joffe S, Escobar GJ, Black SB, Armstrong MA, Lieu TA. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics 1999; 104: 894-9.
49. Marchetti A, Simoes EAF. The economics of RSV infection, prevention, and treatment. In: Weisman LE, Groothius JR (eds). Contemporary Diagnosis and Management of Respiratory Syncytial Virus. Handbooks in Health Care, Newton, PA, 2000; 201-241.